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patients underwent surgery with a total of 52 lesions (mean 
3.5) on radical prostatectomy histology analyses, TPB detected 
36 (70 %) lesions only. Some of these lesions were Gleason 7 
and more mostly located in the posterior basal area of prostate.
Conclusions Transperineal template biopsy technique is 
associated with significantly high prostate cancer detection 
rate in men with previous negative TRUS biopsies, how-
ever compared to radical prostatectomy histology map, a 
significant number of lesions can still be missed in the pos-
terior and basal area of prostate.
Keywords Prostate cancer (PCa) · Transperineal 
template biopsy (TPB) · Multiparametric MRI (mpMRI) · 
Transrectal ultrasound (TRUS) · Diffusion-weighted 
imaging (DWI) · T2-weighted image (T2WI)
Background
Transrectal ultrasound (TRUS)-guided biopsy in men sus-
pected of having prostate cancer has been an established 
clinical practice [1, 2]. Transperineal route of needle biop-
sies under guidance of a TRUS probe is emerging as a sec-
ond line investigation in the diagnostic care pathway, par-
ticularly in men with previous negative biopsies and rising 
PSA [3]. The burgeoning interest in this approach is due to 
improved sampling of anterolateral part of the gland, better 
information on grade and volume of cancer and perhaps a 
reduced risk of infection compared to transrectal route [4, 
5]. However, this approach is still offered in only a small 
percentage of patients, in particular in conjunction with 
pre-biopsy MRI, as shown by an audit carried out on behalf 
of Urological Society of Australia and New Zealand [6, 7]. 
Despite this, several previous studies have confirmed its 
usefulness in men with previous negative biopsies [4].
Abstract 
Purpose Transperineal template prostate (TPB) biopsy has 
been shown to improve prostate cancer detection in men with 
rising PSA and previous negative TRUS biopsies. Diagnostic 
performance of this approach especially MR imaging and 
using reliable reference standard remains scantly reported.
Materials and methods A total of 200 patients, who were pre-
viously TRUS biopsy negative, were recruited in this study. All 
the participants had at least 28-core TPB under general anes-
thetic within 8 weeks of previous negative TRUS biopsies. In 
15 men undergoing laparoscopic radical prostatectomy, pros-
tate specimens were sectioned using custom-made molds and 
analyzed by experienced pathologist as a feasibility study.
Results In total, 120 of 200 patients (60 %) had positive TPB 
biopsy results. All of these men had at least one negative biopsy 
from transrectal route. T2 diffusion-weighted MR imaging 
showed no lesion in almost one-third of these men (61/200; 
30.5 %). Out of these, 33 (33/61; 54 %) showed malignancy 
on TPB including high-grade tumors (>Gleason 7). Out of 15 
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T2-weighted MR images provide useful information 
about prostate anatomy and help in visualization of cancer 
lesions in prostate [8]. MR imaging has been increasingly 
adopted in men with previous negative TRUS biopsies and 
rising PSA. Diagnostic accuracy of T2-weighted imaging 
(WI) varies between 50 and 90 % [9]. Also, data on meth-
ods of imaging and pathology co-orientation, in order to 
compare diagnostic accuracy of MR imaging with radical 
prostatectomy specimen, are lacking.
The recent technological development of rapid prototyp-
ing, a technique by which 2D images are processed into 3D 
computerized physical models, has provided clinicians and 
bioengineers with a new way to understand complex spa-
tial relationships of prostate and potential biopsy-related 
procedural complexities more clearly [10–12]. This allows 
operators physical visualization and device–anatomy ori-
entation in 3D space. Rapid prototyping represents a new 
technology, which is likely to play a significant role in the 
patient-specific planning of prostate and other oncological 
interventions.
There are several studies reporting advantages of trans-
perineal template biopsies (TPB) [13–16]; however, the 
literature comparing its diagnostic accuracy in comparison 
with whole mount prostate specimen is scanty and mostly 
retrospective in nature [14]. There are no studies reporting 
on comparison of multiparametric MRI (mpMRI), template 
biopsies and detailed histology of prostatectomy specimen, 
processed in orientation with the MRI images using 3D 
printing and molds for patient-specific prostate.
In the present study, we investigated diagnostic accuracy 
of TPB in men with previous negative TRUS biopsies in 
particular men with negative MRI and positive TPB biop-
sies. A proof of concept study was also carried out, using 
patient-specific custom-built prostate molds and radical 
prostatectomy histology as a reference standard.
Patients and methods
Study population and patient recruitment
Between January 2013 and June 2015, 200 men with at 
least one previous negative TRUS biopsies and rising 
PSA were offered TPB in a multi-institutional setting. The 
study was registered as an audit project at both participat-
ing centers, and institutional approvals were obtained (Pil-
grim Hospital audit number P2251/2015 and Ninewells 
Hospital, Caldicott, approval number CSAppGN021211). 
All men had MRI imaging of prostate prior to TPB. As a 
proof of concept, we selected fifteen men subsequently opt-
ing for radical prostatectomy (RP) for a detailed analysis of 
the prostate specimen. MRI images were used for 3D print-
ing and custom-created patient-specific molds to enable 
histopathological processing of prostates after RP. Baseline 
characteristics of patients are shown in Table 1. Flow chart 
of the study is shown in Fig. 1.
MR imaging protocol
Most of the MR imaging in the participating centers was 
carried out on 1.5 T scanners (Siemens Medical Solutions), 
equipped with surface phased pelvic array (Body Matrix, 
Siemens Medical Solutions).
Anatomical imaging of the prostatic gland was 
obtained by acquiring turbo spin-echo (TSE) T2-weighted 
sequences in the axial, sagittal and coronal planes, with 
the use of optimized parameters for a better spatial 
resolution.
All patients underwent diffusion-weighted imaging 
(DWI), (2D echo-planar imaging spin-echo, with at least 
three b-values and calculated ADC map) in addition to ana-
tomical T2WI.
The MR imaging was performed for staging purposes 
6–7 weeks post-TRUS biopsy to minimize artifact from 
post-biopsy hemorrhage.
In a small subset of cohort meant for custom-created 
molds, MR imaging was carried out using 3T scanner (TIM 
Trio, Siemens Medical Solutions) using multiparametric 
(mp) approach, with standard protocol in accordance with 
European Society of Uro-radiology Guidelines 2012 [17]. 
The protocol combines anatomical sequences (TSE T2 and 
T1WI) with functional imaging, including DWI sequences 
with three b-values (0,400 and 1000 s/mm2) and a sepa-
rate high b-value (2000 s/mm2) acquisition and dynamic 
contrast-enhanced (DCE) sequences (3D fast gradient-echo 
sequences with temporal resolution of 4 s, using 2 ml/kg 
of Dotarem, gadolinium-based contrast agent [Guerbet, 
France]).
The mpMR images were assessed and scored by experi-
enced uro-radiologist without knowledge of histopathology.
Table 1  Characteristics of the study cohort
Number of patients (%) 200 (100 %)
Age, year, mean (range) 66 (48–78)
PSA level, ng/ml, median (range) 12.5 (8–36)
Prostate volume, cc, median (range) 45 (23–200)
Prostate size
 Left–right, mm, median (IQR) 55 (52–60)
 Apex–base, mm, median (IQR) 42 (38–47)
 Anterior–posterior, mm, median (IQR) 42 (38–47)
Number of previous negative TRUS biopsies (%)
 1 160 (80 %)
 2 26 (13 %)
 3 14 (7 %)
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In accordance with the European consensus meeting 
statement on mpMRI to detect, localize and character-
ize prostate cancer, the prostate images were divided into 
a 27 regions of interest (apical, mid and base quadrants) 
[18]. Regions, which contained suspected lesions, were 
marked as affected area for analyses and comparison with 
histopathology.
T2 and DWI parameters were assessed and lesions 
labeled as suspicious of prostate cancer prior to template 
biopsies. In 40 men, images were acquired using 3T MR 
machine and this includes those where radical prostatec-
tomy specimen were oriented to imaging through mold fab-
rication process described below.
Customized 3D printed molds of prostate specimen 
for histology
The process for patient-specific molds, based on anatomi-
cal MRI (T2WI) and prostate sectioning during histopa-
thology processing, is illustrated in Fig. 2 followed by 
detailed description.
3D segmentation of prostate contour
Participants had 3T mpMRI scans before their preferred 
surgical treatment option (laparoscopic radical prostatec-
tomy). Three planar views (axial, coronal and sagittal) of 
the prostate were obtained by T2-weighted images (T2WI); 
the thickness of each slice was 3 mm with 0.6 mm gap and 
the scan resolution for axial view of 0.63 × 0.63 mm2. 
After a detailed analysis of 2D pelvic images, the bound-
ary of the prostate capsule was traced with the help of an 
experienced uro-radiologist and MIMICS software (Medi-
cal Image Segmentation for Engineering on Anatomy), and 
the segmentation of the prostate was done in one direction 
(mostly axial) and modified in the other two directions (as 
shown in Fig. 3). The model was saved as a stereolithogra-
phy (STL) file.
3D prostate model generation and modification
With the 9–12, T2WI in axial direction of segmentation, 
one 3D model was fused and converted into an object 
simulated in software MIMICS representing patient’s pros-
tate topography. Before any modification, the 3D prostate 
model was verified and compared with the previous T2WI 
to avoid any possible misstatement, which made sure 
mold’s outline was matched with MR images. The cap-
sule of the fused 3D model was fairly rough when verifi-
cation was done so smoothing was applied on the surface 
of capsule. The coarse model was imported to CAD soft-
ware Meshmixer (2011 Autodesk, Inc.) for the purpose of 
smoothing and reducing the difficulty of mold fabrication. 
The smoothed model was also saved in STL file as a mesh 
model and transferred into MIMICS again for triangle 
reduction to reduce the file size.
Fig. 1  Flow chart of study. One of the prostate lesions shows in 
T2-weighted MR images (a, red arrow); template prostate biopsy (b, 
red mass area); prostatectomy specimen slice (c, red arrow); and his-
tology photo (d, red arrow). Asterisk: Pre-TPB is within 8 weeks of 
previous negative TRUS biopsies
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Mold design
The triangle-reduced mesh model was imported into Solid-
Works (3D CAD design software, analysis software, Das-
sault Systèmes SolidWorks Corp. USA) as a SolidWorks 
Part (SLDPRT) model. For a successful conversion, the 
triangle or mesh surfaces of a model had to be controlled 
within a certain limit, and otherwise the importing process 
would have been influenced with a risk of collapse. The 
solid simulated prostate model was then wrapped up by a 
cubic or rectangular model block, and “subtraction” (com-
bined in feature) was applied to the two models. As a result, 
a new model, with an internal cavity for precise holding 
of patient’s prostate, was created, according to individual 
patient’s MRI scans. The outside dimensions of the molds 
were varied because patients had different shapes and sizes 
of prostates. Once the position of prostate in the mold was 
determined, slots for sectioning the specimens were placed 
into the mold with a reasonable location of axial direction 
according to 2D images in axial plane MRI. Each slot was 
1.2 mm thick for an easy cutoff with a single trimming 
blade with thickness of 0.245 mm (Feather Safety Razor 
Co., LTD. Medical Division) and with a 3-mm interval, 
which represented the thickness of each MRI axial slice. 
The orientation of the slots could also be sagittal and coro-
nal, depending on the fusing direction of patients’ prostate 
Fig. 2  Steps of patient-specific molds fabrication and histopathologi-
cal sectioning—1 segmentation of MRI data in biomedical software 
MIMICS, 2 mold fabrication in CAD software SolidWorks, 3 3D 
printout from rapid prototyping machine MakerBot, 4 post-radical 
prostatectomy specimen before dyeing and mold placement, 5 slicing 
of prostate specimen with a single blade, 6 sliced sections shown in 
the mold and 7 specimen slices arranged from apex to base
Fig. 3  Segmentation of the prostate (green area) in three different views of MR imaging, from left to right axial, coronal and sagittal
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model. The mold was then divided into 2 halves (left and 
right) using feature “split” for embedding of prostate speci-
men. The two separated parts, which were edited in SLD-
PRT files, were saved as STL files.
Mold prototyping with fused filament fabrication 
technology
3D fabrication of each mold was done in a 3D printer (Mak-
erBot Replicator 2X). The 3D printer has dual print heads, 
which could create two different parts with fused deposition 
of materials at the same time. Acrylonitrile–butadiene–sty-
rene (ABS) in 1.75 mm (filament diameter), which is made 
of a combination of those three plastics, is the type of print-
ing material for Replicator 2X. The patients’ mold parts 
were printed layer by layer, and the layer height of extruded 
filament could be as small as 100 microns. All solid portions 
of the model parts were automatically printed in the lattice 
of honeycomb for reducing materials usage and print time. 
Printing time ranging from 4 to 7 h was dependant on the 
size of each mold and the applied layer height (from 100 
to 300 microns). Before the final printing, the STL files of 
two mold halves were imported to software MakerWare to 
orient the printing position, calculate the approximate print-
ing time and amount of ABS plastic needed. Rafts were also 
added on the bottom of the two mold halves to provide a 
better build surface and avoid any warping when layers 
closer to the extruder were cooling and shrinking
Specimen dyeing and sectioning
Once the prostate specimen was acquired from a patient 
after surgical removal, it was transferred to pathology 
laboratory and placed in formalin for 48–72 h at room tem-
perature. Before being sliced in the mold, the specimen was 
painted so that the left part was green and right part was 
red, and then the seminal vesicles were excised as per mold 
from apex to base of prostate. When placing the prostate 
specimen into the mold, the right orientation needed to be 
checked so that the sliced histopathology specimens would 
represent their respective MRI scanning slices. During the 
sectioning, a single blade was used to cut the prostate and 
it had to be applied carefully and patiently to avoid speci-
men friction and shifting. After slicing, all histopathology 
sections were photographed and stored in separated tissue 
blocks for further analysis.
Data analysis
Diagnostic accuracy for TPB was assessed for differ-
ent regions and zones of the prostate as shown in Fig. 1. 
The histopathological sections of whole mount specimen 
were used as reference standard in a subset of cohort, as 
described in methods. Further analysis included diagnostic 
accuracy of TPB with regards to grade and size of cancer 
foci in relation to prostate specimen histology.
Results
Mean age of all patients in a cohort was 66 years (range 
48–78), mean prostate volume was 45 cc (range 23–200) 
and mean PSA was 12.5 ng/ml (range 8–36). All men had 
at least one negative TRUS biopsy.
120 (120/200; 60 %) of men were found to have prostate 
cancer confirmed by TPB.
Fig. 4  Patient outcome and 
lesion detection in different 
methods
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In 139 (139/200; 69.5 %) men, MRI scan detected 
at least one suspicious lesion, detecting on average 1–3 
lesions within the gland. Histopathology of TPB showed 
cancer in 84 patients (84/139; 60.4 %).
In 61 (61/200; 30.5 %) patients, no definable lesions 
were seen in prostate on imaging (50 on 1.5 T and 11 on 
3T machine). 36 (36/61; 59 %) of these men were shown to 
have prostate cancer on template biopsies(Fig. 4). Distribu-
tion of cancer foci is shown in Fig. 5. Some of these lesions 
were significant based on previously published criteria [19] 
[20] and patients required radical treatment .
In proof of concept study with orientation of imag-
ing with histopathology, there were 52 lesions seen in 15 
prostate specimens, ranging from size of 2 mm to 3 cm. 
36 of these were correctly identified by TPB (70 %) 
(Fig. 4). Region-wise detection rate for TPB and loca-
tion of suspected lesions on MRI are shown in Table 2. 
This demonstrates that most of the lesions missed by TPB 
are smaller and in the basal posterior region of prostate. 
Table 2 also shows correlation between size of lesions in 
different regions and diagnostic accuracy of TPB approach.
Discussion
The study showed that template biopsies of prostate 
detected cancer in 60 % of men with previous negative 
TRUS biopsies. The detection rate was higher if lesions 
were seen on MR imaging (60.4 vs. 54 %) compared to 
no definable abnormality on MR imaging. Interestingly, 
in more than half men with no definable lesions on 1.5 T 
MR imaging, cancers of various grades were detected on 
TPB. This highlights the fact that post-biopsy MRI can-
not replace histopathology from biopsies as a diagnostic 
Fig. 5  Distribution of cancer 
foci in 36 patients with negative 
MRI and positive TPB
Table 2  Number of foci of 
prostate cancer (PIRAD score 
3 or more) correctly detected 
by template biopsies (TPB) 
and multiparametric MRI 
(mpMRI) versus histopathology 
of laparoscopic radical 
prostatectomy (LRP)
Gleason grade Size of lesions mpMRI TPB LRP (reference)
Anterior Posterior Anterior Posterior Anterior Posterior
Gleason 6 <5 mm 0 (0 %) 3 (50 %) 2 (67 %) 3 (50 %) 3 6
≥5 mm 4 (80 %) 4 (100 %) 5 (100 %) 3 (75 %) 5 4
Gleason 7 <5 mm 2 (50 %) 3 (38 %) 3 (75 %) 5 (63 %) 4 8
≥5 mm 6 (100 %) 7 (100 %) 6 (100 %) 5 (71 %) 6 7
Gleason 8 or more <5 mm 0 (0 %) 0 (0 %) 1 (100 %) 1 (33 %) 1 3
≥5 mm 1 (100 %) 3 (75 %) 0 (0 %) 2 (50 %) 1 4
Sub-total 13 (65 %) 20 (63 %) 17 (85 %) 19 (59 %) 20 32
Total 33 (64 %) 36 (70 %) 52
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modality and area needs further research, using pre-biopsy 
mpMRI protocol, which shows promising detection rate for 
clinically significant cancers [21, 22]. It is quite possible 
that advanced multiparametric imaging using 3T machines 
in all the patients may have picked some of these foci, how-
ever not all centers, especially small district general and 
community hospitals have access to this technology.
Our findings contribute to filling the gap in knowledge 
as highlighted by National Institute of Health and Excel-
lence (NICE) guidelines panel [23].
In the detailed, analysis using patient-specific molds, 
lesions in posterior location near the bases and those 
smaller than 5 mm are missed in almost one in five 
patients. Multiparametric MRI was used to locate abnormal 
foci in all these participants prior to TPB and interestingly 
performs slightly less than transperineal biopsies approach 
especially in anterior prostate region. In smaller lesions less 
than 5 mm, mpMRI did not perform well even for high-
grade disease (31.3 % (5/16) in Gleason 7, 8 and more); 
however, it was much better in lesions more than 5 mm. 
The findings of the study confirm complementary role of 
advanced MR Imaging and improved sampling using TPB 
in better detection and localization of prostate cancer foci.
The study uses 3D printing, also known as rapid proto-
typing to provide an improved orientation between imag-
ing and histopathology data of radical prostatectomy speci-
men which then facilitates assessing diagnostic accuracy 
of template biopsies. This requires a multi-disciplinary 
approach and combined effort of surgeon, bioengineer and 
radiologist. The real use of this technique in the present 
study was to support pathologist in correctly aligning his-
topathological slices of prostate with the MR imaging data. 
This approach improved our understanding of cancer foci 
distribution within the prostate gland and reliable compar-
ison of what is seen in MRI and pathological sectioning. 
Patient-specific molds were created and made available to 
histopathologist prior to sectioning of prostate. The histo-
pathologist was not aware of MRI findings while report-
ing Gleason score of number of cancer foci in the prostate 
specimen. In the future and more data available, 3D print 
may exist in pathology in routine clinical practices, espe-
cially when this involves a low-cost desktop 3D printer 
(Makerbot or Ultimaker) and manufactured molds using 
£0.6 worth of material over the course of 4–7 h, with mini-
mal technical manpower input. Our study may facilitate 
this and future research in this area.
There is ongoing research and innovations to improve 
MR–histology correlation mainly driven by desire to trans-
late predictive value of MRI into clinical practice. Although 
there are a number of factors responsible for variations in 
the reports of sensitivity and specificity of MR imaging 
in visualization and interpretation of tumors on MRI, cor-
relation between MR–histology remains a major one [24, 
25]. Spatial correlation using methodology of the present 
and previously described studies [11, 12] is a step toward 
addressing this issue.
The reported studies have suggested that the ex vivo 
shape of the prostate is considerably different from the 
in vivo contour [26, 27]. In the present study, surface pel-
vic coil was used compared to endorectal coil reported 
previously which compresses the prostate [28]. We have 
studied this issue (unpublished results), and there were no 
significant differences (8 % increase in volume of ex vivo 
prostate specimen) between in vivo prostate imaging and 
ex vivo prostate geometry; however, this remains a theo-
retical risk.
The present study also highlights poor performance of 
TRUS-guided biopsies in sampling disease even in periph-
eral zone close to rectal approach. Some of the previous 
studies suggest saturation biopsies as a second best step; 
however, such an approach is still not ideal for anteriorly 
located tumors. The emerging consensus, although with 
no strong evidence available yet, is that men with negative 
TRUS biopsies and rising PSA should be offered MR imag-
ing for the detection of anteriorly placed prostate cancer 
should be kept in mind. The present study and our clinical 
practice reflect this. As pointed out above, complementary 
performance of both MR imaging and TPB should help in 
improving sampling and detection of prostate cancers both 
in anterior and posterior base regions. Although posterior 
area was much smaller than anterior portion in the transper-
ineal biopsy template, there were 12 more lesions detected 
in posterior area. Both MRI and TPB had similar detection 
rate in posterior portion (63 vs. 59 %), which means more 
samples are needed in this part. Small lesions (<5 mm) 
were still hard for TPB to recognize but was far better than 
MRI. MRI had a higher accuracy in pointing out ≥5-mm 
lesions (93 vs. 78 %). Half of lesions were Gleason Grade 
7; TPB detected 9 out of 10 lesions in anterior but only 10 
out of 15 lesions in posterior.
There was more than one focus of cancers with histo-
logical heterogeneity in all the patients. Which cancer foci 
are significant and may ultimately be responsible for sig-
nificant outcomes such as metastases and death? To answer 
this question, Heffner et al. [29] used whole-genome 
sequencing and molecular pathological analyses to charac-
terize the lethal cell clone in a patient who died of prostate 
cancer. They tracked the evolution of the lethal cell clone 
from the primary cancer to metastases through samples col-
lected during disease progression and at the time of death. 
Surprisingly, these analyses revealed that the lethal clone 
arose from a small, relatively low-grade cancer focus in 
the primary tumor, and not from the bulk, higher-grade pri-
mary cancer or from a lymph node metastasis resected at 
prostatectomy. This interesting but crucial question needs 
further research.
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There was no correlation between the size of prostate 
gland and detection of prostate cancer, although admittedly 
the study was not designed to answer this question. Mean 
size of prostate in this series was 45 cc (range 23–200).
Conclusions
Transperineal template biopsy technique is associated with 
significantly higher prostate cancer detection rate in men 
than previous negative TRUS biopsies, however compared 
to radical prostatectomy histology map, a significant num-
ber of lesions can still be missed in the posterior and basal 
area of prostate. Small but high Gleason Grade cancers 
are still a challenge for TPB although it has a higher per-
formance than mpMRI, based on a small patient sample 
analyzed.
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